What is the difference between bringing a new “drug” to market and bringing a new outcome to market?

What are the storylines of “value” that transition legacy operating models centered on promoting and pushing a product’s technical specifications to creating and positioning business for system advantage?

Sitting in the zone where human and computational assemblages can do extraordinary things, the future of competition in the life sciences industry has less to do with “drug,” and more to do with assuming Total System Leadership for the “common good.” But how do you apply systems thinking to a long-term global market view of healthcare, while avoiding “innovation exhaustion”?

Get answers and foresight into a new industry model that includes reinvesting earnings to sustain the production of heath; join us at the second Signal Series event, “From Price Determining Value to Value Determining Price: It’s About Strategy at a System Level,” on June 25 from 11:00AM–12:00PM EDT.

Click here for additional information and registration details.

Related Content

Evidence Matters 2022

Evidence Matters 2022

Evidence Matters is a virtual one-day summit that brings the literature review community together from different industries to learn, engage, and solve ever-pressing evidence-based research challenges.